Tuis6MK • FRA
add
Merck & Co Inc
Vorige sluiting
€101,80
Dagwisseling
€101,60 - €101,60
Jaarwisseling
€90,70 - €125,00
Markkapitalisasie
288,18Â mjd USD
Gemiddelde volume
370,00
P/V-verhouding
-
Dividend-opbrengs
-
Primêre beurs
NYSE
In die nuus
Finansieel
Inkomstestaat
Inkomste
Netto inkomste
(USD) | Jun. 2024info | J/J-verandering |
---|---|---|
Inkomste | 16,11Â mjd | 7,16% |
Bedryfskoste | 5,42Â mjd | 4,94% |
Netto inkomste | 5,46Â mjd | 191,30% |
Netto winsgrens | 33,86 | 185,20% |
Wins per aandeel | 2,28 | 210,68% |
EBITDA | 8,08Â mjd | 19,52% |
Effektiewe belastingkoers | 9,07% | — |
Balansstaat
Totale bates
Totale aanspreeklikheid
(USD) | Jun. 2024info | J/J-verandering |
---|---|---|
Kontant en korttermynbeleggings | 11,35Â mjd | 78,02% |
Totale bates | 112,63Â mjd | 7,81% |
Totale aanspreeklikheid | 68,98Â mjd | 4,95% |
Totale ekwiteit | 43,65 mjd | — |
Uitstaande aandele | 2,53 mjd | — |
Prys om te bespreek | 5,92 | — |
Opbrengs op bates | 16,06% | — |
Opbrengs op kapitaal | 22,48% | — |
Kontantvloei
Netto kontantverandering
(USD) | Jun. 2024info | J/J-verandering |
---|---|---|
Netto inkomste | 5,46Â mjd | 191,30% |
Kontant van bedrywe | 5,64Â mjd | 52,19% |
Kontant van beleggings | -1,07Â mjd | 90,66% |
Kontant van finansiering | 1,22Â mjd | -67,64% |
Netto kontantverandering | 5,70Â mjd | 239,96% |
Beskikbare kontantvloei | 4,41Â mjd | 50,42% |
Meer oor
Merck & Co., Inc. is an American multinational pharmaceutical company headquartered in Rahway, New Jersey, and is named for Merck Group, founded in Germany in 1668, of which it was once the American arm. The company does business as Merck Sharp & Dohme or MSD outside the United States and Canada. It is one of the largest pharmaceutical companies in the world, generally ranking in the global top five by revenue.
Merck & Co. was originally established as the American affiliate of Merck Group in 1891. Merck develops and produces medicines, vaccines, biologic therapies and animal health products. It has multiple blockbuster drugs or products each with 2020 revenues including cancer immunotherapy, anti-diabetic medication and vaccines against HPV and chickenpox.
The company is ranked 71st on the 2022 Fortune 500 and 87th on the 2022 Forbes Global 2000, both based on 2021 revenues. In 2023, the company’s seat in Forbes Global 2000 was 73. Wikipedia
Gestig
01 Jan. 1891
Webwerf
Werknemers
71Â 000